Sporanox: Potent Antifungal Therapy for Systemic Infections
Sporanox
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $6.30 | $63.00 (0%) | 🛒 Add to cart |
| 20 | $5.40 | $126.00 $108.00 (14%) | 🛒 Add to cart |
| 30 | $4.93 | $189.00 $148.00 (22%) | 🛒 Add to cart |
| 60 | $4.70 | $378.00 $282.00 (25%) | 🛒 Add to cart |
| 90 | $4.50 | $567.00 $405.00 (29%) | 🛒 Add to cart |
| 120 | $4.30 | $756.00 $516.00 (32%) | 🛒 Add to cart |
| 180 | $4.10 | $1134.00 $738.00 (35%) | 🛒 Add to cart |
| 270 | $4.00 | $1701.00 $1080.00 (37%) | 🛒 Add to cart |
| 360 | $3.89
Best per pill | $2268.00 $1400.00 (38%) | 🛒 Add to cart |
Sporanox (itraconazole) is a broad-spectrum triazole antifungal agent indicated for the treatment of systemic fungal infections. As a potent inhibitor of ergosterol synthesis, it disrupts fungal cell membrane integrity, offering a critical therapeutic option for invasive mycoses. This medication is particularly valuable in immunocompromised patients and those with refractory infections, providing a well-established efficacy profile against a range of pathogenic fungi. Proper diagnosis and monitoring are essential for optimal treatment outcomes.
Features
- Active ingredient: Itraconazole 100mg
- Formulation: Capsules, oral solution, and intravenous infusion
- Mechanism: Inhibition of fungal cytochrome P450-dependent 14α-demethylase
- Spectrum: Active against Aspergillus, Blastomyces, Histoplasma, Candida species
- Bioavailability: Enhanced by acidic gastric environment; take with food
Benefits
- Effectively treats severe, systemic fungal infections that may be life-threatening
- Provides broad-spectrum coverage against both yeast and mold pathogens
- Offers multiple administration routes for flexible treatment approaches
- Demonstrates good tissue penetration, including lung, liver, and skin
- Suitable for long-term maintenance therapy in appropriate clinical scenarios
- Well-established clinical data supporting efficacy in diverse patient populations
Common use
Sporanox is commonly prescribed for the treatment of blastomycosis, histoplasmosis, and aspergillosis in patients who are intolerant of or refractory to amphotericin B therapy. It is also used for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes, and oropharyngeal and esophageal candidiasis. Off-label uses may include treatment of other endemic fungal infections and certain cases of refractory superficial fungal infections when standard therapies have failed.
Dosage and direction
Dosage varies significantly based on indication, patient factors, and formulation. For systemic fungal infections: typically 200-400mg daily in divided doses. For onychomycosis: pulsed dosing of 200mg twice daily for one week per month for 2-3 months. Always take capsules with a full meal to enhance absorption. The oral solution should be taken on an empty stomach. Swallow capsules whole; do not crush or chew. Duration of treatment ranges from weeks to months depending on infection type and clinical response. Hepatic function and drug levels should be monitored during prolonged therapy.
Precautions
Monitor liver function tests before and during treatment. Use with caution in patients with cardiac disease or risk factors for heart failure. Assess for drug interactions before initiation. Not recommended during pregnancy unless potential benefit justifies potential risk. Exercise caution in elderly patients and those with renal impairment. Educate patients about signs of hepatotoxicity and congestive heart failure. Avoid simultaneous administration with CYP3A4 substrates. Consider therapeutic drug monitoring in serious infections.
Contraindications
Contraindicated in patients with known hypersensitivity to itraconazole or any component of the formulation. Do not administer to patients taking certain medications metabolized by CYP3A4 that can cause serious adverse events, including quinidine, dofetilide, levacetylmethadol, pimozide, or ergot alkaloids. Contraindicated in patients with evidence of ventricular dysfunction or history of heart failure. Avoid use in patients with chronic obstructive pulmonary disease, particularly those requiring long-term oxygen therapy.
Possible side effects
Common side effects include nausea, vomiting, diarrhea, abdominal pain, headache, and rash. Elevated liver enzymes occur in approximately 5% of patients. Less frequently reported effects include hypertension, hypokalemia, edema, and fatigue. Serious adverse effects may include clinical hepatitis, cholestasis, symptomatic heart failure, peripheral neuropathy, and hearing loss. Rare cases of serious skin reactions, including Stevens-Johnson syndrome, have been reported. Most side effects are dose-dependent and reversible upon discontinuation.
Drug interaction
Sporanox is a potent inhibitor of CYP3A4 and P-glycoprotein, resulting in numerous clinically significant interactions. Avoid concomitant use with cisapride, triazolam, oral midazolam, quinidine, dofetilide, levacetylmethadol, pimozide, ergot alkaloids, lovastatin, simvastatin, and certain HIV protease inhibitors. Dose adjustments may be necessary for warfarin, digoxin, cyclosporine, tacrolimus, benzodiazepines, calcium channel blockers, and certain antiretroviral agents. Drugs that reduce gastric acidity (H2 antagonists, proton pump inhibitors) may significantly decrease itraconazole absorption.
Missed dose
If a dose is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Do not double the dose to make up for a missed dose. Maintain regular dosing schedule to ensure consistent therapeutic levels. If multiple doses are missed, contact healthcare provider for guidance on resuming therapy. Consistent administration is particularly important for pulsed dosing regimens used in onychomycosis treatment.
Overdose
Symptoms of overdose may include enhanced adverse effects, particularly nausea, vomiting, and diarrhea. Severe overdose may lead to pronounced hepatotoxicity, hypokalemia, hypertension, and potentially cardiac effects. There is no specific antidote. Treatment is supportive and symptomatic. Gastric lavage may be considered if ingestion was recent. Monitor hepatic and renal function, electrolyte status, and cardiac parameters. Dialysis is not likely to be effective due to high protein binding.
Storage
Store at room temperature (15-30°C or 59-86°F) in original container. Protect from light and moisture. Keep tightly closed. Do not store in bathroom or other humid areas. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. The oral solution should not be frozen. Intravenous formulation requires specific storage conditions as per manufacturer instructions.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Sporanox is a prescription medication that should only be used under the supervision of a qualified healthcare professional. Individual response to therapy may vary. Always follow your healthcare provider’s instructions regarding dosage, administration, and monitoring. Report any adverse effects to your physician promptly. The complete prescribing information should be consulted before initiating therapy.
Reviews
Clinical studies demonstrate Sporanox efficacy rates of 70-85% in appropriately selected patients with systemic fungal infections. Dermatology studies show complete cure rates of approximately 50-60% in onychomycosis with pulsed dosing regimens. Many clinicians appreciate its broad spectrum and oral bioavailability, though monitoring requirements and drug interaction potential are frequently noted considerations. Patient satisfaction varies with indication, with higher satisfaction in life-threatening systemic infections compared to cosmetic indications like onychomycosis where efficacy must be balanced against monitoring requirements.